A new look at cancer survivors' media habits shows that where they get data and to what degree they value it depends on when they were diagnosed.
Even as consumers push back against health data sharing, its use for marketing will continue to grow.
The eye drug star has nabbed an FDA nod as a 12-week formulation in wet AMD and is expected to get into diabetic retinopathy next May.
All eyes are on Eli Lilly’s Trulicity as it faces down new competition. But the drugmaker just notched an important trial win that shows it can hang with its…
The sublingual Dsuvia can only be administered by a healthcare professional in medically supervised settings such as hospitals.
Is Pfizer’s Lyrica leaving the TV ad game? Facing patent expiration, the stalwart top 10 TV spender dropped its budget to $3.8 million in October.
Pfizer’s oncology unit is on a roll. On Friday, the FDA approved its third cancer-fighter from the New York drugmaker in the past two months.
Promius Pharma's new digital and social media push empowers people with skin conditions under the banner “My Skin Matters.”
Critics of Takeda’s $62 billion Shire buyout have fretted lately about the company’s hemophilia standing. But immunology is a different story.
Celgene’s Revlimid may have slipped in previously untreated follicular lymphoma. But in the second-line setting, the drug has a win.